Anti-CEACAM1 and Anti-PD Antibody Combination for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy approaches lack effective combinatorial antibody-based therapies that target distinct or parallel mechanisms of cancer progression, limiting their efficacy in treating various types of cancer.
Innovation Solution
The use of combinations of anti-CEACAM1 antibodies and antibodies that disrupt the binding of PD-1 to its natural ligands, PD-L1, administered sequentially to enhance lymphocyte-mediated cytotoxicity against cancer cells, with anti-CEACAM1 antibodies increasing PD-L1 expression on cancer cells, thereby synergistically attenuating tumor progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current single-antibody immunotherapy approaches are used, then treatment simplicity is maintained, but therapeutic efficacy is limited
Solution Approach 1:
The patent combines two different antibodies (anti-CEACAM1 and anti-PD-1/PD-L1) into a single therapeutic regimen to achieve synergistic anti-tumor effects. This merging of multiple therapeutic mechanisms resolves the contradiction by improving efficacy through combination therapy while managing complexity through standardized sequential administration protocols
2Reliability
If combination antibody therapy is implemented, then therapeutic efficacy is improved, but treatment complexity increases
Solution Approach 1:
The patent establishes predetermined sequential administration protocols where anti-CEACAM1 antibody is administered first, followed by anti-PD-1/PD-L1 antibody at specified time intervals. This preliminary planning of the treatment sequence resolves the contradiction by simplifying operational complexity through standardized protocols while maintaining the efficacy benefits of combination therapy
3Reliability
If lymphocyte cytotoxicity is enhanced through antibody combination, then tumor progression is attenuated, but treatment duration may increase
Solution Approach 1:
The patent employs periodic administration schedules where antibody treatments are given at specific intervals to maintain therapeutic effect while allowing for optimal immune response cycles. This periodic approach resolves the contradiction by achieving sustained tumor inhibition through rhythmically timed doses rather than continuous treatment, thereby managing treatment duration
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3
AI summary
The present invention provides compositions comprising anti-CEACAM1 antibodies, compositions comprising antibodies capable of inhibiting or blocking the interaction between PD-1 and its ligands, and methods for their combined use in treating cancer.